Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled multicenter study of IBI355 in Sjögren's syndrome
CTR20263481Phase 2Active
- Sponsor
- InnoCare Pharma
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of IBI-355 in Sjögren's syndrome, sponsored by InnoCare Pharma. Started Sep 2026; status: active.
02
Drugs
IBI-355
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on CTR20263481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263481.